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20 Inﬂuence of gestational age and day of life on IRT and PAP in
cystic ﬁbrosis screening
L. Mense1, M. Stopsack2, J. Hammermann1. 1University Hospital Carl Gustav
Carus, Dresden, Department of Pediatrics, Dresden, Germany; 2Dresden University
of Technology, Institute of Clinical Chemistry and Laboratory Medicine, Dresden,
Germany
Objectives: The determination of immunoreactive trypsin (IRT) and pancreatitis-
associated protein (PAP) in dried blood spots is one possibility of conducting a
neonatal cystic ﬁbrosis screening. In the present study we examined the inﬂuence
of gestational age and day of life on IRT and PAP.
Methods: Data from the newborn screening center of Dresden, Germany in
the years from 2008 to 2010 were studied. IRT measurement was done with
AutoDELFIA Kit (PerkinElmer Turku). PAP measurement with MucoPAP Kit
(DYNABIO Marseille). All specimen were tested on IRT and for samples exceeding
50 ng/ml PAP measurement was added. For this study we analyzed all data of
newborn screening cards which were taken in the age of 36−72 h after birth and
contained information of gestational age.
Results: 42,607 newborn screening results met the inclusion criteria. In 1889 cases
determination of PAP was executed. While IRT showed a minor correlation to ges-
tational age (r = −0.058, p< 0.001), PAP was strongly correlated to gestational age
(r = 0.540, p< 0.001). PAP and IRT correlated strongly as well (r = 0.484, p< 0.001).
Day of life showed only a minor correlation to IRT (r = −0.035, p< 0.001) and PAP
as well (r = −0.050, p = 0.029).
Conclusion: A severe inﬂuence of gestational age on IRT could not be seen
while PAP was strongly affected. Therefore, borderline PAP results in preterm
infants should be interpreted carefully. To avoid screening failure in preterm babies
control samples and sweat testing should be initiated liberally even after completed
32 weeks of gestation (ﬁnal time for other screenings).
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Background: SARLES introduces the use of Pancreatitis Associated Protein (PAP)
as second step after IRT elevation in newborn screening for Cystic Fibrosis (CF) to
minimize the problems with low IRT speciﬁty, parental stress and delayed diagnosis
after 2. IRT and unwanted carrier detection.
Methods: IRT measurement was done with AutoDELFIA Kit (PerkinElmer Turku),
PAP measurement with MucoPAP Kit (DYNABIO Marseille). Blood samples
taken 36 to 72 h after birth, gestational age >32 weeks, were tested for IRT.
For samples exceeding 50 ng/ml PAP measurement was added. All newborns with
result combinations IRT 50 ng/ml and PAP 1.8 ng/ml or IRT 100 ng/ml and
PAP 1.0 ng/ml or those with IRT 150 ng/ml alone were referred to pilocarpin
iontophoresis. To improve sensitivity and speciﬁty of marker combination, induce-
ment of further diagnosis was set on IRT cut off value 60 ng/ml and for IRT*PAP
product 100.
Results: We tested 50,693 newborn samples. 1135 (2.2%) of them had
IRT 50 ng/ml and got PAP measurement, whereof 110 (0.21%) were further
elevated in IRT/PAP combination according to SARLES. The use of the higher
IRT cut off together with IRT*PAP product would have reduced the recall rate to
93 (0.18%) and detected all known cases of CF from screened population (by now
seven patients) and from selective analyses (18 patients, 3 of them don’t fullﬁll
SARLES criteria).
Conclusion: Biochemical CF screening by IRT*PAP product leads to improved
recall rate and appreciable increased sensitivity. Compared to mutation analysis
it avoids undesirable carrier identiﬁcation and high analysis costs. Compared to
IRT/IRT strategy it avoids second blood sample and prolonged parental stress.
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The objective was to evaluate the performance of a neonatal immunoreactive
trypsin(ogen) (IRT) kit used with the new Genetic Screening Processor (GSP®).
The new GSP® IRT kit is based on the current AutoDELFIA® IRT kit chemistry
(a time-resolved immunoﬂuorometric assay), which was modiﬁed to be compatible
with the GSP® instrument.
Precision, interference, correlation, and screening performance of the new GSP®
IRT kit (catalog number 3306–0010) was studied using dried blood spots as
samples. Precision of the GSP® IRT kit was below 8.5% throughout the measuring
range (9–500 ng/mL blood) even when a stored calibration curve (run 20−24 h
earlier) was used. Icteric, lipemic, and hemolytic specimens did not interfere with
the assay; neither did EDTA, Na-citrate, or Li-heparin. The correlation between
the GSP® IRT and the B005–212 AutoDELFIA® IRT kits was found to be
y = 0.94×−0.35 (weighted Deming regression). The newborn population medians
and upper percentiles were similar with the methods compared. The IRT values of
all 12 conﬁrmed CF-positive cases tested were clearly separated from unaffected
cases with both the GSP® IRT and the AutoDELFIA® IRT kits, i.e. the CF cases
were above the 99th percentile of the newborn population (n = 2106). The stability
studies showed that the reagents (assay buffer, tracer) were stable for 14 days in
the cooled reagent carousel of the instrument.
The new GSP® IRT kit offers the beneﬁts of the new GSP® instrument (easy
to use, high throughput, calibration curve valid for 24 hours, barcoded reagents
with long on-board time) while preserving the excellent performance of the current
AutoDELFIA® IRT kit.
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Newborns with cystic ﬁbrosis (CF) have increased blood immunoreactive trypsino-
gen (b-IRT) concentrations. Even if the speciﬁcity of an initial positive b-IRT test
is not elevated, the sensitivity proved to be high.
Aim of this study was to analyze the differences in b-IRT levels among neonates
positive to newborn screening (NBS), who were then classiﬁed as classic CF, CFTR-
RD, carriers and non-carriers in order to evaluate the predictive value of b-IRT.
Population data included all b-IRT positive (>99th centile) neonates born in
Lombardia from 2000 to 2007. The hypertrypsinaemic newborns were divided into
four groups, according to the CF status. b-IRT measurement was undertaken using
time-resolved ﬂuoroimmunoassay and DNA analysis was performed on blood spot
by Oligonucletide Ligation Assay.
Seven thousand three hundred and ﬁfty-four newborns were found positive to NBS
and were included in the study. An overall statistically signiﬁcant difference in
b-IRT levels was found among the four groups (p< 0.001), while b-IRT values did
not differ between non carrier and carrier groups. Measurement of b-IRT had a
low predictive accuracy in correctly identifying the four different groups (c-index:
0.60), but the accuracy of b-IRT is high in discriminating between classical CF and
carrier or non carrier neonates positive to NBS.
In conclusion, these results suggest that neonatal b-IRT concentrations may be in
part determined by the genetic status. Although neonatal b-IRT concentrations may
be considered as one of the phenotypic variables associated with different genotypes,
a wide range of individual variation may occur.
